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Abstract
It is unclear whether cancer and its treatments increase the risk of adverse pregnancy outcomes. 
Our aim was to examine whether cancer survivors have higher risks of poor outcomes in 
pregnancies conceived after diagnosis than women without cancer, and whether these risks differ 
by cancer type and race. Diagnoses from cancer registries were linked to pregnancy outcomes 
from birth certificates in three U.S. states. Analyses were limited to the first, live singleton birth 
conceived after diagnosis. Births to women without a previous cancer diagnosis in the registry 
were matched to cancer survivors on age at delivery, parity, race/ethnicity, and education. Log-
binomial regression was used to estimate risk ratios. Cervical cancer survivors had higher risks of 
preterm birth (Risk ratio=2.8, 95% Confidence interval: 2.1, 3.7), as did survivors of invasive 
breast cancer (RR=1.3, 95% CI: 1.1, 1.7) and leukemia (RR=2.1, 95% CI: 1.3, 3.5). We observed a 
higher risk of small for gestational age (SGA) infants (<10% of weight for age based on a national 
distribution) in survivors of brain cancer (RR=1.7, 95% CI: 1.1, 2.8) and extranodal non-Hodgkin 
lymphoma (RR=2.3, 95% CI: 1.5, 3.6). We did not see an increased risk of infants born preterm, 
low birth weight, or SGA in pregnancies conceived after ductal carcinoma in situ, thyroid cancer, 
melanoma, or Hodgkin lymphoma. While our results are reassuring for survivors of many cancers, 
some will need closer monitoring during pregnancy.
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Introduction
Advances in cancer treatment and screening have led to a dramatic increase in the number of 
cancer survivors.1 At the same time, maternal age at first birth has steadily increased, 
meaning that a growing number of women have not achieved their desired family size at the 
time of cancer diagnosis.2 Women diagnosed with cancer during their reproductive years say 
that, after survival, pregnancy is their most important concern, with an estimated 57–70% of 
all patients aged 40 or younger wanting children after cancer.3–5 Although there is growing 
evidence from fertility studies that some cancer treatments can damage the female 
reproductive system, less is known about pregnancy outcomes in the many women who are 
able to conceive after cancer.
Preterm birth is a leading cause of neonatal death worldwide, and infants born early are at 
higher risk of lifelong effects including cerebral palsy, developmental disabilities, and 
cognitive impairment.6 In the United States, 10% of live births are preterm (<37 weeks 
gestation) and 8% are low birth weight (<2,500g). The risks are higher among African-
American women, who have a 13% risk of preterm delivery and of low birth weight.7
Several population-based studies in Europe have found a higher risk of preterm birth in 
pregnancies conceived after cancer.8–10 However, few of these studies were powered to 
stratify by cancer type. Grouping different cancers may obscure risks specific to each 
diagnosis. Only one population-based study, limited to reproductive cancers, has been able 
to calculate risks specific to African-American women.11
The aim of this study was to determine whether risks of adverse pregnancy outcomes are 
higher in cancer survivors than women who have not had cancer, and whether the risk 
differences comparing cancer survivors with comparison women without cancer vary by 
race.
Material and Methods
To identify births to women with a previous cancer history, cancer registry staff in three U.S. 
states linked cancer diagnosis data to vital records. Cancer registries in the states of Georgia, 
North Carolina, and Tennessee all used the same linking protocol, which was developed by 
the Georgia Cancer Registry and incorporated both deterministic and probabilistic methods 
(see Supplement). Women diagnosed with any reportable invasive cancer12 or ductal 
carcinoma in situ (DCIS) between the ages of 20 and 45 were eligible. The study included 
cancers diagnosed August 23, 1993 to August 22, 2012 linked to births from 1994 to 2012 in 
Georgia (cancer diagnoses before 1999 were from metropolitan Atlanta only), cancers 
diagnosed August 23, 1999 to August 22, 2013 linked to births from 2000–2013 in North 
Carolina, and cancers diagnosed Jan. 1, 2004 to August 22, 2013 linked to births from May 
20, 2004–2013 in Tennessee.
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We identified the first pregnancy reaching 20 weeks that was conceived after a cancer 
diagnosis in each state. Although stillbirths were included to determine the first pregnancy 
after cancer, these deliveries were excluded from multivariate analysis because a high 
proportion of stillbirths had missing values for matching variables. Women diagnosed during 
pregnancy were excluded.
Live births from the same period were eligible for the comparison group if there was no 
record of cancer diagnosis in the state’s registry during the years covered by the study. 
Comparison women were matched to cancer survivors within the same state on four primary 
confounders recorded on the birth certificate: mother’s exact age at delivery (single-year 
categories), race and ethnicity (7 categories: Hispanic ethnicity of any race, non-Hispanic 
white, African American, Asian, Pacific Islander, Native American, and multiracial women 
of any ethnicity), parity (0, 1, 2, and ≥3), maternal education (college graduate yes or no). 
For the three most common cancers (invasive breast, melanoma, and thyroid) a random 
sample of comparison births were matched 5:1 to cancer survivor births. For cancer 
diagnoses with smaller sample sizes (brain, cervical, DCIS, Hodgkin lymphoma, leukemia 
and both nodal and extranodal non-Hodgkin lymphoma), comparison women were matched 
25:1 to decrease random error. For both cancer survivors and comparison women, we limited 
our analyses to singleton births between 20 and 44 weeks completed gestation, to mothers 
who were between the ages of 20 and 45 at the time of delivery.
Cancer Type
Cancer type was classified by primary site and histology, using site recode values from the 
Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer 
Institute.
Outcomes
The primary analyses assessed whether cancer survivors were at higher risk of adverse 
outcomes recorded in vital records: preterm birth (<37 weeks gestation), very preterm birth 
(<32 weeks gestation), low birth weight (<2,500g), very low birth weight (<1,500g), low 
birth weight at term (<2,500g at ≥37 weeks gestation), and small for gestational age (SGA), 
defined as below the 10th percentile of birth weight for gestational age and sex based on a 
national distribution.13 A small number of infants with implausible combinations of birth 
weight and gestational age, based on the values used by Alexander et al.,14 were excluded. 
Secondary outcomes included whether the mother delivered by Cesarean section, and 
whether the infant had an Apgar score <7 at 5 minutes or was admitted to the neonatal 
intensive care unit (NICU).
Covariates
To identify potential confounders of the association between cancer diagnosis and adverse 
pregnancy outcomes, we used both the literature and bivariate associations in our data to 
inform a causal diagram. Based on the diagram, the variables available in vital records that 
we considered as potential confounders, in addition to the matching factors, included the 
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mother’s self-reported smoking during pregnancy and marital status. These variables were 
not included in the final models because after we matched on maternal age, race/ethnicity, 
parity, and education, adding these covariates to the model did not change the estimates of 
effect. Two measures of household income — women’s eligibility for public health 
insurance through Medicaid and for food assistance from the Women, Infants, and Children 
(WIC) program — were available for all years in Tennessee, 2008–2012 in Georgia, and 
2011–12 in North Carolina. We conducted a sensitivity analysis to assess whether adding 
either of these measures of household income to the model changed the results. We also 
conducted a sensitivity analysis adding pre-pregnancy BMI to the model for breast cancer 
and preterm birth for cancer survivors in Tennessee.
Statistical methods
The study population was described using frequencies, proportions, and risks. Log-binomial 
models were used to estimate risk ratios. Separate models were fit for each cancer diagnosis 
and outcome, so that the risk ratio compares women with a specific cancer to women 
without a previous cancer diagnosis.
In stratified analyses, risk ratios and risk differences for breast, reproductive cancers, and 
thyroid cancers were calculated separately for white women and African-American women. 
Reproductive cancers were grouped in stratified analyses because there was insufficient 
sample size to estimate measures of effect for individual reproductive cancers. To assess 
whether the effects of cancer diagnosis differ by race, we estimated the interaction contrast 
(IC) using linear binomial regression. Interaction contrasts represent the risk difference for 
the estimated effect of cancer diagnosis among white women, subtracted from the risk 
difference among African-American women.
Risk ratios are reported for associations with sample sizes of at least 10 adverse pregnancy 
outcomes in survivors of each cancer type. Analyses were conducted using SAS 9.4 (SAS 
Institute, Inc., Cary, NC).
Results
Among the 4,203 eligible women with a live birth conceived after cancer, the most common 
cancer types were melanoma (23%), thyroid cancer (23%), breast cancer (18%), Hodgkin 
lymphoma (7%), and cervical cancer (3%) (Appendix Table A1). Women who gave birth 
after a cancer diagnosis were older, more educated, more likely to be married, and more 
likely to be having their first child than women without cancer whose births were eligible to 
be sampled for the matched comparison group (Table 1).
The characteristics of mothers at the first birth after a diagnosis differed by cancer type. 
Breast cancer survivors were older at the time of delivery than melanoma and cervical 
cancer survivors. In these three U.S. states, 35% of all breast cancer survivors and 25% of 
both cervical and Hodgkin lymphoma survivors were African-American.
Infants born to survivors of certain cancers were at higher risk of low birth weight, due to 
being born preterm or small for gestational age (SGA). Births to women with a history of 
Hartnett et al. Page 4
Int J Cancer. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
invasive breast cancer were more likely to be preterm (RR for delivery before 37 weeks=1.3, 
95% CI: 1.1, 1.7) and very preterm (RR for delivery before 32 weeks=1.7, 95% CI: 1.0, 2.8) 
than those to matched comparison women (Table 2). Infants born to survivors of invasive 
breast cancer also had higher risks of other outcomes associated with prematurity (Tables 2 
and 3), including low birth weight (RR for <2,500g=1.6, 95% CI: 1.3, 2.0), very low birth 
weight (RR for <1,500g=2.1, 95% CI: 1.3, 3.6), and 5-minute Apgar score below 7 (RR=1.8, 
95% CI: 1.1, 2.9). The RR for NICU admission among infants born to breast cancer 
survivors was 1.5 (95% CI: 0.9, 2.6). The risk of SGA in infants born to invasive breast 
cancer survivors was similar to the risk in comparison women (RR=1.2, 95% CI: 0.9, 1.5).
There was a high risk of preterm birth in cervical cancer survivors (Table 2), with 28% of 
live births delivered before 37 weeks (RR=2.8, 95% CI: 2.1, 3.7), and 10% delivered before 
32 weeks (RR=5.4, 95% CI: 3.1, 9.6). Infants born to cervical cancer survivors also had 
higher risks of low birth weight (RR=2.8, 95% CI: 2.0, 4.0) and very low birth weight 
(RR=4.3, 95% CI: 2.3, 8.2) than infants born to matched comparison women, and were more 
likely to be delivered by C-section (RR=1.5, 95% CI: 1.3, 1.8). However, infants born to 
cervical cancer survivors did not have a higher risk of being born SGA than infants born to 
comparison women (RR=0.7, 95% CI: 0.4, 1.4).
Infants born to leukemia survivors were more likely to be preterm (RR=2.1, 95% CI: 1.3, 
3.5) and low birth weight (RR=2.2, 95% CI: 1.2, 4.1). The RR comparing the risk of SGA 
births in leukemia patients to matched comparison women was 1.5 (95% CI: 0.8, 2.7). There 
was a higher risk of SGA in infants born to brain cancer survivors than matched comparison 
women (RR=1.7, 95% CI: 1.1, 2.8), with 16/104 (15%) born SGA. However, only 1 of the 
16 infants born SGA to brain cancer survivors was small enough to be classified low birth 
weight at term (Table 2). Of the 63 infants born to survivors of extranodal non-Hodgkin 
lymphoma, 16 were SGA (RR=2.3, 95% CI: 1.5, 3.6) and 11 were low birth weight 
(RR=2.0, 95% CI: 1.1, 3.5).
Although the risk of delivering by C-section was slightly higher for survivors of most 
cancers (Table 3), women diagnosed with DCIS, Hodgkin lymphoma, melanoma, and 
thyroid cancer did not have a higher estimated risk of any other adverse outcome in their 
first live birth after diagnosis than matched comparison women (Tables 2 and 3).
A risk ratio for the association between cancer diagnosis and stillbirth was not estimated 
because a high proportion of stillbirths were missing values of one or more matching factors. 
However, the crude risk of stillbirth did not appear higher in births to cancer survivors than 
the general population. Among eligible pregnancies after a cancer diagnosis that reached 20 
weeks, 0.7% (30/4,582) ended in stillbirth, which was the same as the risk (also 0.7%) in all 
unmatched eligible pregnancies to women without a cancer diagnosis in these three U.S. 
states.
African-American cancer survivors had higher overall risks of adverse pregnancy outcomes 
than white cancer survivors (Table 4). The disparity was starkest for thyroid cancer, where 
African-American survivors had a 17% risk (95% CI: 11%, 24%) of low birth weight in the 
first pregnancy conceived after diagnosis, compared with 5% (95% CI: 4%, 7%) in white 
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survivors. But because African-American women also had much higher baseline risks of 
adverse outcomes, the excess risk attributable to breast and thyroid cancer was not 
meaningfully different for African-American women than white women. For all three 
pregnancy outcomes, the risk differences comparing white breast cancer survivors to white 
women without cancer were nearly the same as the risk differences comparing African-
American breast cancer survivors to African-American women without cancer (Interaction 
Contrast=0.02, 95% CI: −0.04, 0.08 for preterm birth; 0.03, 95% CI: −0.03, 0.09 for low 
birth weight, and 0.04, 95% CI: −0.02, 0.09 for SGA). Interaction contrasts comparing risk 
differences in white and African-American women after thyroid cancer were similarly null. 
However, white women did have a higher risk of low birth weight after reproductive cancer 
than white women without cancer (14% after cancer vs. 5% in comparison women), while 
African-American women did not have an increase in risk associated with cancer (14% vs. 
13%) (Table 4).
The results did not change substantially when we: 1) added BMI to the model for preterm 
birth in breast cancer survivors from Tennessee, 2) controlled for household income as 
measured by eligibility for public health insurance through the Medicaid program, 3) 
controlled for household income as measured by eligibility for nutrition assistance through 
the WIC program, or 4) excluded women diagnosed with a more than one cancer before 
conception of the pregnancy.
Discussion
This large, multistate, population-based study allowed us to analyze the risks of adverse 
pregnancy outcomes specific to the most common cancer types of young adulthood. We 
observed a high risk of preterm delivery in cervical cancer survivors, whose risks of preterm 
birth and low birth weight were three times higher than in women without a history of 
cancer. In infants born to breast cancer survivors, we saw a slightly higher risk of preterm 
birth than in women without cancer, and a moderately higher risk of low birth weight. 
Although the sample sizes were small, we observed an increased risk of preterm birth and 
low birth weight in infants born to leukemia survivors and SGA in infants born to women 
diagnosed with brain cancer and extranodal non-Hodgkin lymphoma. Aside from slightly 
higher risks for delivery by C-section, we did not see a higher risk of adverse pregnancy 
outcomes after DCIS, Hodgkin lymphoma, melanoma, or thyroid cancer.
Previous studies have found a slightly elevated risk of some adverse pregnancy outcomes in 
cancer survivors compared with women who have not had cancer, with odds ratios (ORs) for 
preterm birth between 1.3 and 1.5.8–11 When comparing all women with any previous 
cancer diagnosis to matched women without cancer, we see a similar overall association 
(RR=1.2, 95% CI: 1.1, 1.3). However, this study suggests that the increased risks are limited 
to certain cancers. Our results are consistent with population-based studies in Denmark that 
did not observe increased risks of preterm birth or low birth weight at term in infants born to 
women diagnosed with Hodgkin lymphoma15 or melanoma.16 Our estimated RR for preterm 
birth in breast cancer survivors was 1.3 (95% CI: 1.0, 1.6). A Danish study of births to breast 
cancer survivors diagnosed between 1943 and 2002 had a similar result, although with a 
wider confidence interval reflecting that study’s smaller sample size (OR=1.3, 95% CI: 0.7, 
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2.2).17 We similarly found higher risks of very preterm birth in survivors of invasive breast 
cancer (RR=1.7, 95% CI: 1.0, 2.8).
For most cancers, the increased risk of infants born low birth weight appears to be the result 
of preterm birth rather than growth restriction. A similar study of survivors in Finland, 
which included all cancers diagnosed in both childhood and adulthood, also reported 
increased odds of low birth weight and preterm birth in all cancer survivors, but no overall 
increased odds of infants born small for gestational age.8
Cancer treatment in adulthood might increase the risk of early delivery through different 
mechanisms. Surgery for cervical cancer could structurally weaken the cervix and reduce its 
capacity to serve as a barrier against infection.18 Some types of chemotherapy might cause 
preterm birth through immunosuppression, reducing survivors’ ability to combat infections 
associated with preterm birth.19,20 Although it is unclear how long immunosuppression may 
persist after different treatment regimens, studies in breast cancer patients have found CD4+ 
counts that remained 50% below baseline 12–14 months after treatment21 and weaker 
vaccine response in survivors with a mean of 2.6 years since chemotherapy.22 Although 
closer management of pregnancies in women with a history of cancer could result in more 
iatrogenic preterm births, we did not see evidence of this in our data. Among infants born 
preterm, 15.4% of deliveries in cancer survivors were induced, similar to the 14.7% of 
deliveries in matched comparison women that were induced.
Although we did not see an increase in risk in infants born SGA after diagnosis with most 
cancers, we did observe higher risks of this outcome in infants born to survivors of brain 
cancer and extranodal non-Hodgkin lymphoma. Cranial radiation for brain cancer and other 
cancers of the head and neck has been linked to long-term damage to the hypothalamic-
pituitary-adrenal (HPA) axis,23–25 which plays an important role in fetal growth.26 
Extranodal non-Hodgkin lymphoma can involve any organ in the body, so depending on the 
location of the tumor, some patients receive cranial radiation.27 Patients with 
abdominopelvic lymphomas can receive radiation to the pelvic field, which researchers have 
hypothesized might lead to intrauterine growth restriction in subsequent pregnancies through 
fibrosis, endometrial injury, reduced uterine volume, or poorer vascularization.23 However, 
our small sample sizes for brain cancer and extranodal non-Hodgkin lymphoma warrant a 
cautious interpretation of these associations, which may be chance findings.
In this study, African-American survivors of breast, reproductive, and thyroid cancers had 
higher risks of adverse outcomes after cancer than white women. But these higher risks 
mostly reflected the high baseline risks of adverse outcomes in African-American women, 
rather than a larger increase in risk after cancer diagnosis. Our observation of an increased 
risk of low birth weight risk after reproductive cancer among white women, but not among 
African-American women, is largely consistent with results from the only other paper 
examining risks by race.11 However, for breast cancer, the previous study using birth records 
linked to cancer diagnosis data in the state of Florida found higher risks of low birth weight 
after breast cancer in African-American women, but not in white women. In contrast, we 
observed nearly identical small increases in risk among women of both races. One key 
difference is that the Florida study included women diagnosed with cancer during the 
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pregnancy or immediately after delivery (who thus may have had undetected cancer during 
the pregnancy), while our study was limited to pregnancies conceived after diagnosis.
This study has important strengths, including its population-based design and large sample 
of African-American women. With more than 4,000 first births after cancer, our study is the 
largest of pregnancy outcomes in cancer survivors to date.
The quality of cancer diagnosis information in U.S. cancer registries is high, with a study 
finding 96% sensitivity for detection of cancer cases and a mean of 95% accuracy across 13 
variables.28 Although the quality of birth certificate data differs by variable and state, studies 
of U.S. vital records have consistently shown that the pregnancy outcomes of low birth 
weight, Apgar score, and delivery method, as well as all four matching factors (maternal 
age, race/ethnicity, parity, and education), have excellent agreement with both medical 
records and maternal self-report.29–32 Preterm delivery from the obstetric estimate of 
gestational age has generally good agreement with medical records,30,33,34 although both 
birth certificates and medical records may misclassify preterm delivery, particularly in 
women who did not plan their pregnancies.
One limitation of the study is that the U.S. does not have a national cancer registry, so cancer 
diagnosis information is specific to each state. Thus, to be correctly identified, a woman’s 
first birth after cancer must have occurred in the same state as her diagnosis. Women who 
were diagnosed in one state and then gave birth in another state are missing from this 
analysis. We are also unable to correctly identify cancer survivors diagnosed before the years 
covered by the study. It is thus likely that we are missing a disproportionate number of 
survivors who had a long interval between diagnosis and the first birth after cancer, because 
these women are more likely to have been diagnosed in years before we have registry data 
and because they had more time to move to a different state before delivery. While having 
cancer data only from recent years is thus a limitation of the study, it is also a strength, 
because the survivors identified in our study all received modern cancer treatments. Counts 
of stillbirths to cancer survivors in this study need to be interpreted with caution, because the 
stillbirth records were more often incomplete. A higher proportion of stillbirth records than 
live births were missing key variables used in the link, including Social Security number, the 
unique identifier assigned to each U.S. citizen. This could cause us to underestimate the true 
number of stillbirths to cancer survivors if true matches were missed, or to overestimate the 
true number of stillbirths if there were false matches between different women who shared 
other linking factors like name and date of birth.
Future studies should use other data sources to examine outcomes including stillbirth, early 
pregnancy loss, and birth defects, and should focus on risks after less common cancers that 
we had insufficient sample size to analyze. Our study suggests that survivors of some 
cancers need closer monitoring and management in pregnancy. However, the results are 
reassuring for many survivors of cancer diagnosed in young adulthood; we did not observe 
an increased risk of adverse pregnancy outcomes after many cancer diagnoses.
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Novelty and Impact
In pregnancies conceived after diagnosis, infants born to cervical cancer survivors were 
three times more likely to be preterm than infants born to matched comparison women 
without a cancer history. Infants born to breast cancer and leukemia survivors also had a 
higher risk of preterm birth. In contrast, infants born to survivors of Hodgkin lymphoma, 
melanoma, and thyroid cancer did not have a higher risk of being born preterm or small 
for gestational age.
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Figure 1. 
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Table 4
Risks, risk differences, and risk ratios for preterm birth, low birth weight, and small for gestational age in the 
first live singleton birth conceived after diagnosis with breast, reproductive, and thyroid cancers, compared 
with births to matched comparison women without a previous cancer diagnosis, stratified by race.
Breast Reproductive Thyroid
Preterm birth
 White women
  Risk, cancer survivors 12% (9%, 15%) 18% (13%, 24%) 9% (7%, 12%)
  Risk, matched comparison births (ref) 9% (8%, 10%) 8% (8%, 9%) 9% (8%, 10%)
  Risk Difference 3% (−1%, 6%) 9% (4%, 15%) 0% (−2%, 3%)
  Risk Ratio 1.3 (1.0, 1.8) 2.1 (1.6, 2.9) 1.1 (0.8, 1.4)
 African-American women
  Risk, cancer survivors 20% (15%, 25%) 22% (14%, 33%) 20% (13%, 28%)
  Risk, matched comparison births (ref) 15% (13%, 17%) 14% (13%, 16%) 17% (14%, 20%)
  Risk Difference 4% (−1%, 10%) 8% (−1%, 18%) 2% (−5%, 10%)
  Risk Ratio 1.3 (1.0, 1.7) 1.6 (1.0, 2.4) 1.1 (0.8, 1.7)
 Interaction Contrast 0.02 (−0.04, 0.08) −0.01 (−0.12, 0.10) 0.02 (−0.06, 0.10)
Low birth weight
 White women
  Risk, cancer survivors 9% (7%, 12%) 14% (9%, 20%) 5% (4%, 7%)
  Risk, matched comparison births (ref) 7% (6%, 8%) 5% (5%, 6%) 6% (5%, 7%)
  Risk Difference 2% (−1%, 5%) 9% (4%, 14%) 0% (−2%, 1%)
  Risk Ratio 1.4 (1.0, 1.9) 2.7 (1.9, 3.9) 0.9 (0.7, 1.3)
 African-American women
  Risk, cancer survivors 18% (14%, 24%) 14% (7%, 24%) 17% (11%, 24%)
  Risk, matched comparison births (ref) 13% (11%, 15%) 13% (11%, 14%) 11% (9%, 14%)
  Risk Difference 6% (1%, 11%) 2% (−6%, 10%) 5% (−2%, 12%)
  Risk Ratio 1.4 (1.1, 1.9) 1.1 (0.6, 2.0) 1.5 (0.9, 2.3)
 Interaction Contrast 0.03 (−0.03, 0.09) −0.07 (−0.17, 0.02) 0.06 (−0.01, 0.13)
Small for gestational age
 White women
  Risk, cancer survivors 8% (6%, 11%) 8% (5%, 13%) 8% (6%, 10%)
  Risk, matched comparison births (ref) 9% (8%, 10%) 9% (8%, 9%) 8% (7%, 9%)
  Risk Difference −1% (−4%, 2%) 0% (−4%, 4%) 0% (−2%, 2%)
  Risk Ratio 0.9 (0.6, 1.3) 1.0 (0.6, 1.6) 1.0 (0.7, 1.3)
 African-American women
  Risk, cancer survivors 17% (13%, 22%) 13% (6%, 23%) 12% (7%, 19%)
  Risk, matched comparison births (ref) 14% (12%, 16%) 15% (14%, 17%) 15% (13%, 18%)
  Risk Difference 3% (−2%, 8%) −2% (−10%, 5%) −3% (−9%, 3%)
  Risk Ratio 1.2 (0.9, 1.6) 0.9 (0.5, 1.5) 0.8 (0.5, 1.3)
Int J Cancer. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hartnett et al. Page 20
Breast Reproductive Thyroid
 Interaction Contrast 0.04 (−0.02, 0.09) −0.02 (−0.11, 0.07) −0.03 (−0.09, 0.04)
*
Reproductive cancers include cervix uteri, corpus uteri, ovary, vulva, and all other female genital cancers. Comparison women without cancer 
were matched 5:1 to breast and thyroid cancer survivors and 25:1 to reproductive cancer survivors on exact age at birth (single-year category), 
parity (0, 1, 2, 3+), race and ethnicity (Hispanic, non-Hispanic white, African American, Asian, Pacific Islander, Native American, and multiracial 
of any ethnicity), maternal education (college graduate yes or no) and state of residence (GA, NC, or TN).
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